Millipore Sigma Vibrant Logo

News Release

November 18, 2019
Your Contact:
Phone: +49 6151 72 44461

Merck Wins R&D 100 Award for First-to-Market Biopharma Purification Innovation

  • Eshmuno® CP-FT Resin yields 10x higher capacities than traditional methods
  • First cation exchange resin developed for flow-through removal of aggregates using frontal chromatography

Darmstadt, Germany, November 18, 2019 — Merck today announced it has received a prestigious R&D 100 Award for its Eshmuno® CP-FT Resin, a first-to-market product used in biopharmaceutical manufacturing. The R&D 100 Awards honor the 100 most innovative and significant technologies introduced in the past year. Merck has received 10 R&D 100 Awards in the past seven years.

“This award recognizes our innovation in research and development for a product that helps biomanufacturers bring new therapies to patients faster and more cost effectively,” said Udit Batra, CEO, Life Science at Merck. “Congratulations to our extended teams, who live our purpose every day by solving the toughest problems in life science in collaboration with the global scientific community.”

Aggregates are impurities in monoclonal antibody drugs that can reduce efficacy and therefore pose significant risk to patients. These impurities are challenging to remove in the purification process of drug manufacturing. Merck’s Eshmuno® CP-FT resin is a tool that removes aggregates, delivering capacities 10 times higher than traditional bind/elute chromatography. The significant reduction in resin and buffer volume results in a smaller manufacturing footprint as well as lower costs. The Eshmuno® CP-FT resin is part of Merck’s BioContinuum™ Polishing Platform.

The R&D 100 Awards are among the most prestigious innovation awards in the world, honoring research and development pioneers. Merck representatives will accept the award at the 57th Annual R&D 100 Awards gala in San Francisco, California on December 5.

Follow Merck on Twitter @Merckgroup, on Facebook @merckgroup and on LinkedIn.


メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。